Patent · US Active

Fused thiazole derivatives as kinase inhibitors

US8093238B2 · kind B2 · utility

0Cited by
1References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 10, 2007
Grant dateJan 10, 2012
Priority date—
Expiry dateMay 19, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D513/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.